Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) - Net Assets
Based on the latest financial reports, Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has net assets worth CN¥1.17 Billion CNY (≈ $170.51 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.21 Billion ≈ $323.53 Million USD) and total liabilities (CN¥1.05 Billion ≈ $153.02 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 688621 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.17 Billion |
| % of Total Assets | 52.7% |
| Annual Growth Rate | 64.9% |
| 5-Year Change | 471.56% |
| 10-Year Change | N/A |
| Growth Volatility | 95.56 |
Beijing Sun Novo Pharmaceutical Research Co Ltd - Net Assets Trend (2017–2024)
This chart illustrates how Beijing Sun Novo Pharmaceutical Research Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Beijing Sun Novo Pharmaceutical Research for the complete picture of this company's asset base.
Annual Net Assets for Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2024)
The table below shows the annual net assets of Beijing Sun Novo Pharmaceutical Research Co Ltd from 2017 to 2024. For live valuation and market cap data, see Beijing Sun Novo Pharmaceutical Research (688621) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.10 Billion ≈ $161.35 Million |
+4.29% |
| 2023-12-31 | CN¥1.06 Billion ≈ $154.71 Million |
+16.41% |
| 2022-12-31 | CN¥908.23 Million ≈ $132.90 Million |
+18.01% |
| 2021-12-31 | CN¥769.64 Million ≈ $112.62 Million |
+298.95% |
| 2020-12-31 | CN¥192.92 Million ≈ $28.23 Million |
+62.45% |
| 2019-12-31 | CN¥118.76 Million ≈ $17.38 Million |
+60.87% |
| 2018-12-31 | CN¥73.82 Million ≈ $10.80 Million |
+122.01% |
| 2017-12-31 | CN¥33.25 Million ≈ $4.87 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Beijing Sun Novo Pharmaceutical Research Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6271.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥563.36 Million | 51.19% |
| Common Stock | CN¥112.00 Million | 10.18% |
| Other Components | CN¥425.27 Million | 38.64% |
| Total Equity | CN¥1.10 Billion | 100.00% |
Beijing Sun Novo Pharmaceutical Research Co Ltd Competitors by Market Cap
The table below lists competitors of Beijing Sun Novo Pharmaceutical Research Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Arena REIT
AU:ARF
|
$945.94 Million |
|
Guangdong Enpack Packaging Co Ltd
SHE:002846
|
$946.46 Million |
|
Firefly Metals Ltd
AU:FFM
|
$946.50 Million |
|
Criteo Sa
NASDAQ:CRTO
|
$946.82 Million |
|
Berliner Effektengesellschaft AG
F:BFV
|
$945.14 Million |
|
Smartgroup Corporation Ltd
AU:SIQ
|
$945.10 Million |
|
Piraeus Port Authority S.A
AT:PPA
|
$945.00 Million |
|
Dynavox Group
ST:DYVOX
|
$944.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Beijing Sun Novo Pharmaceutical Research Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,040,012,428 to 1,100,637,054, a change of 60,624,626 (5.8%).
- Net income of 177,409,487 contributed positively to equity growth.
- Dividend payments of 38,153,978 reduced retained earnings.
- Other factors decreased equity by 78,630,883.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥177.41 Million | +16.12% |
| Dividends Paid | CN¥38.15 Million | -3.47% |
| Other Changes | CN¥-78.63 Million | -7.14% |
| Total Change | CN¥- | 5.83% |
Book Value vs Market Value Analysis
This analysis compares Beijing Sun Novo Pharmaceutical Research Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.88x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 156.28x to 5.88x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥0.37 | CN¥57.68 | x |
| 2018-12-31 | CN¥0.91 | CN¥57.68 | x |
| 2019-12-31 | CN¥1.04 | CN¥57.68 | x |
| 2020-12-31 | CN¥3.13 | CN¥57.68 | x |
| 2021-12-31 | CN¥6.80 | CN¥57.68 | x |
| 2022-12-31 | CN¥8.01 | CN¥57.68 | x |
| 2023-12-31 | CN¥9.29 | CN¥57.68 | x |
| 2024-12-31 | CN¥9.80 | CN¥57.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Beijing Sun Novo Pharmaceutical Research Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.12%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.45%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 1.81x
- Recent ROE (16.12%) is below the historical average (22.19%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 5.81% | 5.49% | 0.33x | 3.23x | CN¥-1.43 Million |
| 2018 | 27.54% | 15.37% | 0.67x | 2.68x | CN¥13.19 Million |
| 2019 | 40.64% | 20.30% | 0.82x | 2.45x | CN¥35.74 Million |
| 2020 | 38.32% | 20.86% | 0.90x | 2.04x | CN¥53.55 Million |
| 2021 | 13.87% | 21.40% | 0.40x | 1.63x | CN¥29.47 Million |
| 2022 | 17.45% | 23.13% | 0.46x | 1.63x | CN¥66.80 Million |
| 2023 | 17.76% | 19.82% | 0.50x | 1.79x | CN¥80.76 Million |
| 2024 | 16.12% | 16.45% | 0.54x | 1.81x | CN¥67.35 Million |
Industry Comparison
This section compares Beijing Sun Novo Pharmaceutical Research Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,208,953,488
- Average return on equity (ROE) among peers: 9.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) | CN¥1.17 Billion | 5.81% | 0.90x | $945.32 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $7.31 Billion | 1.28% | 4.15x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $591.07 Million | 1.62% | 0.52x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $727.05 Million | 11.51% | 0.20x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $275.56 Million | 21.50% | 1.16x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $552.92 Million | 0.39% | 0.01x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $1.15 Billion | 23.74% | 0.91x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $292.94 Million | 7.42% | 0.73x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $4.71 Billion | 7.43% | 1.93x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $26.34 Billion | 6.76% | 0.18x | $3.30 Billion |
About Beijing Sun Novo Pharmaceutical Research Co Ltd
Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of drugs in China. The company operates external preparation platform that focuses on the research and development of new drugs and generic drugs for skin external preparations; children's clinical data bridging research center; pediatric drug research and development platform;… Read more